Decision: Favourable

Study Title:

A 52-week, randomised, double-blind, double-dummy, parallel group, multi-centre, non-inferiority study assessing exacerbation rate, additional measures of asthma control and safety in adult and adolescent severe asthmatic participants with an eosinophilic phenotype treated with GSK3511294 compared with mepolizumab or benralizumab.

  • NREC Code:


  • Decision:


  • Meeting Date:


  • Study Type:

    CT application

  • Principal Investigator:

    Dr Desmond Michael Murphy

  • PI Institution:

    Cork University Hospital

  • Sponsor:

    IQVIA on behalf of GlaxoSmithKline Research & Development Limited

Scroll to Top